Table 2.

Multivariable analysis of factors evaluated for an association with overall survival, based on 334 patients with molecular subtype available.

Characteristic	Univariate analyses		Multivariable Model A.		Multivariable Model B.
	Unadjusted HR (95% CI)	P	Adjusted HR (95% CI)	P	Adjusted HR (95% CI)	P
Age at surgery (years)a	1.15 (1.03,1.28)	0.01	1.10 (0.98,1.23)	0.11	1.10 (0.98,1.24)	0.09
ASA score		0.07		0.26		0.57
<3 (N = 174)	Reference		Reference		Reference
≥3 (N = 160)	1.24(0.98,1.57)		1.15 (0.90,1.46)		1.07 (0.84,1.37)
Preoperative albumin		0.01		0.03		0.12
≥3.5 g/dL (N = 140)	Reference		Reference		Reference
<3.5 g/dL (N = 39)	1.75 (1.20, 2.56)		1.70 (1.15, 2.49)		1.51 (1.02, 2.23)
Not available (N = 155)	1.06 (0.83,1.37)		1.16 (0.90,1.50)		1.12 (0.87,1.45)
FIGO stage		<0.001		0.08		0.12
IIIA/B (N = 27)	Reference		Reference		Reference
IIIC (N = 228)	2.28 (1.40, 3.70)		1.39 (0.79, 2.46)		1.28 (0.72, 2.29)
IV (N = 79)	3.06 (1.82, 5.14)		1.80 (0.98,3.30)		1.65 (0.89, 3.06)
Intraperitoneal dissemination pattern		<0.001		0.04		0.36
Pelvic (N = 29)	Reference		Reference		Reference
Lower abdominal (N = 48)	2.00 (1.16, 3.44)		1.74 (0.95,3.19)		1.38 (0.73, 2.62)
Upper abdominal/miliary (N = 257)	2.73 (1.72,4.34)		2.02 (1.17,3.51)		1.54 (0.84, 2.80)
Molecular subtype		0.009		0.13		0.47
Non-mesenchymal (N = 240)	Reference		Reference		Reference
Mesenchymal (N = 94)	1.41 (1.09,1.82)		1.23 (0.94, 1.60)		1.10 (0.84,1.45)
Residual disease (cm)		<0.001				<0.001
0 (N = 101)	Reference				Reference
0.1–0.5 (N = 131)	1.83 (1.36, 2.46)				1.34 (0.96,1.88)
0.6–1.0 (n = 36)	2.84(1.89,4.26)				2.07 (1.34, 3.22)
>1.0 (N = 55)	3.40 (2.35,4.91)				2.59 (1.74, 3.86)

Abbreviations: ASA, American Society of Anesthesiologists; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio.

^aHazard ratio per 10-year increase in age.